203 related articles for article (PubMed ID: 38416633)
21. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
22. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
24. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q; Guo N; Chen J; Parks D; Tian Z
J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
[TBL] [Abstract][Full Text] [Related]
25. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
26. Management of Pulmonary Arterial Hypertension.
Weatherald J; Varughese RA; Liu J; Humbert M
Semin Respir Crit Care Med; 2023 Dec; 44(6):746-761. PubMed ID: 37369218
[TBL] [Abstract][Full Text] [Related]
27. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
[TBL] [Abstract][Full Text] [Related]
28. Electrocardiographic Abnormalities and Their Association with Outcomes in Randomized Clinical Trials of Pulmonary Arterial Hypertension.
Minhas J; Moutchia J; Al-Naamani N; Mazurek JA; Holmes JH; Appleby D; Smith KA; Fritz JS; Pugliese SC; Palevsky HI; Kawut SM
Ann Am Thorac Soc; 2024 Jun; 21(6):858-865. PubMed ID: 38241602
[No Abstract] [Full Text] [Related]
29. Prostanoids for pulmonary arterial hypertension.
Galiè N; Manes A; Branzi A
Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012
[TBL] [Abstract][Full Text] [Related]
30. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement.
Fattouch K; Sbraga F; Bianco G; Speziale G; Gucciardo M; Sampognaro R; Ruvolo G
J Card Surg; 2005; 20(2):171-6. PubMed ID: 15725144
[TBL] [Abstract][Full Text] [Related]
31. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
32. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
[TBL] [Abstract][Full Text] [Related]
33. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
34. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
35. [Long-term experience with trerpostinil infusion treatment in patients with pulmonary arterial hypertension in the Czech Republic].
Jansa P; Ambroz D; Maresová J; Jelínková L; Polácek P; Palecek T; Aschermann M; Linhart A
Vnitr Lek; 2007 Apr; 53(4):333-7. PubMed ID: 17578162
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
37. Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis.
Zhang H; Li X; Huang J; Li H; Su Z; Wang J
Medicine (Baltimore); 2016 Jan; 95(4):e2575. PubMed ID: 26825901
[TBL] [Abstract][Full Text] [Related]
38. Medical therapies for pulmonary arterial hypertension.
Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
[TBL] [Abstract][Full Text] [Related]
39. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
Barst R
Int J Clin Pract Suppl; 2010 Nov; (168):23-32. PubMed ID: 20939843
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.
Pan HM; McClelland RL; Moutchia J; Appleby DH; Fritz JS; Holmes JH; Minhas J; Palevsky HI; Urbanowicz RJ; Kawut SM; Al-Naamani N
Eur Respir J; 2023 Jul; 62(1):. PubMed ID: 37169384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
